81 filings
6-K
OKYO
OKYO Pharma Ltd
8 May 24
OKYO Pharma Announces Participation in May 2024 Investor Conferences
7:00am
6-K
OKYO
OKYO Pharma Ltd
30 Apr 24
Current report (foreign)
7:00am
6-K
OKYO
OKYO Pharma Ltd
8 Apr 24
Current report (foreign)
7:00pm
6-K
OKYO
OKYO Pharma Ltd
4 Apr 24
Current report (foreign)
6:30am
6-K
OKYO
OKYO Pharma Ltd
2 Apr 24
Current report (foreign)
7:00am
6-K
0it6qaoiq9wu4
29 Mar 24
Current report (foreign)
2:30pm
6-K
snh4qc
22 Mar 24
Current report (foreign)
7:00am
6-K
3zc7t12ikoot1cp
21 Mar 24
OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial
7:00am
6-K
diqhpo47
20 Mar 24
OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event
8:07am
6-K
9b3dibbm
9 Feb 24
OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain
7:00am
6-K
6r2zbvbawrzx3ttciyu
31 Jan 24
Current report (foreign)
7:00am
6-K
g5ch09v
8 Jan 24
Current report (foreign)
7:00am
6-K
o0t4 k9r6uwmse
5 Jan 24
Current report (foreign)
9:30am
6-K
pxj qn25lsh4by
21 Dec 23
Current report (foreign)
7:35am
6-K
uy9eipe
18 Dec 23
Current report (foreign)
4:56pm
6-K
xmbzahn
4 Dec 23
OKYO Pharma Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit
7:00am
6-K
pvshxitj4atn9gu8u6jv
29 Nov 23
Current report (foreign)
7:00am
6-K
1qf13haxulix
1 Nov 23
Current report (foreign)
4:55pm
6-K
bwj5l5opf2sqo
31 Oct 23
OKYO Pharma Announces $5.84 Million cash raise and payables reduction
7:00am
6-K
473u0jmb0 1uis3jftq
10 Oct 23
Current report (foreign)
7:00am